WallStSmart

Chimerix Inc (CMRX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 250% more annual revenue ($742,000 vs $212,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CMRX earns a higher WallStSmart Score of 29/100 (F).

CMRX

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -6.73

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CMRX2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
1325.0%10/10

Revenue surging 1325.0% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CMRX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$801.08M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CMRX

The strongest argument for CMRX centers on Revenue Growth, Debt/Equity. Revenue growth of 1325.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CMRX

The primary concerns for CMRX are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CMRX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

CMRX is growing revenue faster at 1325.0% — sustainability is the question.

CMRX generates stronger free cash flow (-19M), providing more financial flexibility.

Bottom Line

CMRX scores higher overall (29/100 vs 24/100) and 1325.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chimerix Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?